Emergent BioSolutions Inc (EBS)
2.19
-0.10
(-4.37%)
USD |
NYSE |
Apr 24, 10:15
Emergent BioSolutions Cash from Investing (Quarterly): -11.40M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -11.40M |
| September 30, 2023 | -18.90M |
| June 30, 2023 | 257.70M |
| March 31, 2023 | -15.10M |
| December 31, 2022 | -45.40M |
| September 30, 2022 | -271.60M |
| June 30, 2022 | -32.10M |
| March 31, 2022 | -32.20M |
| December 31, 2021 | -45.80M |
| September 30, 2021 | -55.20M |
| June 30, 2021 | -67.00M |
| March 31, 2021 | -56.10M |
| December 31, 2020 | -36.90M |
| September 30, 2020 | -45.70M |
| June 30, 2020 | -45.10M |
| March 31, 2020 | -24.20M |
| December 31, 2019 | -36.10M |
| September 30, 2019 | -15.30M |
| June 30, 2019 | -24.10M |
| March 31, 2019 | -21.40M |
| December 31, 2018 | -848.50M |
| September 30, 2018 | -26.10M |
| June 30, 2018 | -11.00M |
| March 31, 2018 | -11.60M |
| December 31, 2017 | -207.52M |
| Date | Value |
|---|---|
| September 30, 2017 | -12.78M |
| June 30, 2017 | -9.301M |
| March 31, 2017 | -20.30M |
| December 31, 2016 | -19.96M |
| September 30, 2016 | -17.00M |
| June 30, 2016 | -21.03M |
| March 31, 2016 | -18.21M |
| December 31, 2015 | -11.83M |
| September 30, 2015 | -13.95M |
| June 30, 2015 | -10.60M |
| March 31, 2015 | -9.082M |
| December 31, 2014 | -17.26M |
| September 30, 2014 | -5.221M |
| June 30, 2014 | -4.81M |
| March 31, 2014 | -182.76M |
| December 31, 2013 | -9.354M |
| September 30, 2013 | -44.42M |
| June 30, 2013 | -6.444M |
| March 31, 2013 | -7.679M |
| December 31, 2012 | -12.90M |
| September 30, 2012 | -10.02M |
| June 30, 2012 | -8.592M |
| March 31, 2012 | -8.598M |
| December 31, 2011 | -18.34M |
| September 30, 2011 | -15.81M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-271.60M
Minimum
Sep 2022
257.70M
Maximum
Jun 2023
-32.66M
Average
-36.10M
Median
Dec 2019
Cash from Investing (Quarterly) Benchmarks
| Avid Bioservices Inc | -7.323M |
| Viking Therapeutics Inc | 35.73M |
| FibroGen Inc | 10.24M |
| Avinger Inc | 0.00 |
| RAPT Therapeutics Inc | 20.64M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 32.10M |
| Cash from Financing (Quarterly) | 4.70M |
| Free Cash Flow | -257.90M |
| Free Cash Flow Per Share (Quarterly) | 0.3973 |
| Free Cash Flow to Equity (Quarterly) | 22.30M |
| Free Cash Flow to Firm (Quarterly) | 40.41M |
| Free Cash Flow Yield | -230.0% |